Sign In
Buy ACRX
$0.86
+0 (+0%)
At Close: Apr 08, 2024
Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates
09:35pm, Thursday, 12'th May 2022 Zacks Investment Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -1.01% and 29.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Q1 Earnings Lag Estimates
09:35pm, Tuesday, 10'th May 2022 Zacks Investment Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -80% and 2.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program
12:00pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
Key Opinion Leaders participating will be Stuart Goldstein, MD, Cincinnati Children’s Hospital and Lakhmir Chawla, MD, former Chief of the Division of Intensive Care Medicine at the Washington D.C
AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers
03:28pm, Wednesday, 16'th Mar 2022 Seeking AlphaAcelRx stock falls 15% after HC Wainwright downgrade on ''disappointing quarter''
04:02pm, Monday, 14'th Mar 2022 Seeking Alpha
AcelRx Pharmaceuticals <> was downgraded by H.C
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2022
03:03pm, Monday, 14'th Mar 2022 Benzinga
Upgrades
Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter, compared to $2.39 in
AcelRx stock falls 18% following Q4 results (NASDAQ:ACRX)
03:38pm, Friday, 11'th Mar 2022 Seeking Alpha
AcelRx Pharmaceuticals <> stock fell following its Q4 results.Q4 total revenue declined to $2K, compared to $738K in Q4 2020. The company said 8.96K units of opioid pain drug…
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q4 2021 Results - Earnings Call Transcript
04:55am, Friday, 11'th Mar 2022 Seeking AlphaAcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q4 2021 Results - Earnings Call Transcript
11:55pm, Thursday, 10'th Mar 2022
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q4 2021 Results - Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates
10:15pm, Thursday, 10'th Mar 2022 Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 99.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals GAAP EPS of -$0.06 beats by $0.01, revenue of $0.2M misses by $1.65M
09:08pm, Thursday, 10'th Mar 2022 Seeking Alpha
AcelRx Pharmaceuticals press release (ACRX): Q4 GAAP EPS of -$0.06 beats by $0.01.Revenue of $0.2M (-73.0% Y/Y) misses by $1.65M.
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
09:01pm, Thursday, 10'th Mar 2022 PR Newswire
HAYWARD, Calif., March 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter…
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates
06:48pm, Thursday, 10'th Mar 2022
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 99.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals Q4 2021 Earnings Preview (NASDAQ:ACRX)
10:35pm, Wednesday, 09'th Mar 2022 Seeking Alpha
AcelRx Pharmaceuticals (NASDAQ:ACRX) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is -$0.07 (+30.0% Y/Y) and…
Aziyo Biologics, Inc. (AZYO) Reports Q4 Loss, Lags Revenue Estimates
11:25pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -28.13% and 2.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc
